Melanoma Clinical Trials in Baltimore

Showing 41-60 of 320 trials

Postmarketing Prospective Study of Melanoma Patients Treated With IMLYGIC® to Characterize Risk of Herpetic Infection

NCT02910557

A postmarketing Cohort study of Melanoma patients treated with IMLYGIC (Talimogene Laherparepvec) in clinical Practice to Characterize the risk of herpetic infection with detection of Talimogene Laherparepvec DNA among patients, close contacts, and health care providers; and long term safety in treated patients for up to 5 years after the first IMLYGIC dose.

MelanomaHerpetic Infection

Amgen187 participantsStarted Aug 2017

Coral Springs, Florida, United States • Baltimore, Maryland, United States • Jefferson City, Missouri, United States +20 more locations

Active Not RecruitingPhase 2< 1 mile

Avelumab With or Without Cetuximab in Treating Patients With Advanced Skin Squamous Cell Cancer

NCT03944941

This phase II trial studies how well avelumab with or without cetuximab work in treating patients with skin squamous cell cancer that has spread to other places in the body. Immunotherapy with monoclonal antibodies, such as avelumab and cetuximab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.

Skin Squamous Cell CarcinomaMetastatic Skin Cancer

Alliance for Clinical Trials in Oncology60 participantsStarted Jun 2019

Birmingham, Alabama, United States • Anchorage, Alaska, United States • Anchorage, Alaska, United States +425 more locations

Postmarketing Prospective Study of Melanoma Patients Treated With IMLYGIC® to Characterize Risk of Herpetic Infection

Avelumab With or Without Cetuximab in Treating Patients With Advanced Skin Squamous Cell Cancer

Melanoma Trials in Other Cities

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head)

A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma

A Study to Assess Adjuvant Immunotherapy With Nivolumab Plus Relatlimab Versus Nivolumab Alone After Complete Resection of Stage III-IV Melanoma

BI-1808 as a Single Agent and With Pembrolizumab (KEYTRUDA® ) in Treatment of Advanced Malignancies(Keynote-D20)

Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions

Genetic Analysis of Blood and Tissue Samples From Patients With Advanced Cancer, Moonshot Study

Nilotinib Plus Dabrafenib/Trametinib or Encorafenib/Binimetinib in Metastatic Melanoma

A Study to Evaluate the Efficacy and Safety of Autogene Cevumeran (RO7198457) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Participants With Previously Untreated Advanced Melanoma.

A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7502175 as a Single Agent and in Combination With Checkpoint Inhibitor in Participants With Locally Advanced or Metastatic Solid Tumors

A Study of Modakafusp Alfa (TAK-573) Given by Itself and Together With Pembrolizumab in Adults With Advanced or Metastatic Solid Tumors

ADP-A2M4CD8 as Monotherapy or in Combination With Either Nivolumab or Pembrolizumab in HLA-A2+ Subjects With MAGE-A4 Positive Tumors (SURPASS)

Hybrid Effectiveness-Implementation Trial to Integrate Precision Skin Cancer Risk Feedback in FQHCs

IN10018 Monotherapy and Combination Therapy for Metastatic Melanoma

A Study of Safety and Efficacy of KFA115 Alone and in Combo With Pembrolizumab in Patients With Select Advanced Cancers

Patient Satisfaction With Appearance, Scar Outcome and Quality of Life After Skin Cancer Surgery

A Study of MGC026 in Participants With Advanced Solid Tumors

A Study to Learn About the Long-Term Health of Adult Participants From a Previous Study of a New Melanoma Treatment

Other Conditions in Baltimore